Biotargeted nanomedicines for cancer: six tenets before you begin

Author:

Goldberg Michael S1,Hook Sara S2,Wang Andrew Z3,Bulte Jeff WM4,Patri Anil K5,Uckun Fatih M6,Cryns Vincent L7,Hanes Justin,Akin Demir8,Hall Jennifer B5,Gharkholo Nastaran9,Mumper Russell J10

Affiliation:

1. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA

2. Center for Strategic Scientific Initiatives, Office of the Director, National Cancer Institute, NIH, Bethesda, MD 20892, USA

3. Department of Radiation Oncology, School of Medicine, University of North Carolina, Chapel Hill, NC 27514, USA

4. Russell H Morgan Department of Radiology & Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

5. Nanotechnology Characterization Laboratory, National Cancer Institute, Frederick, MD 21702, USA

6. Department of Pediatrics, Keck School of Medicine, University of Southern California, & Children’s Center for Cancer & Blood Diseases/Children’s Hospital Los Angeles, Los Angeles, CA 90033, USA

7. Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI 53706, USA

8. Department of Radiology, School of Medicine, Stanford University, Palo Alto, CA 94305, USA

9. Center for Nanotechnology in Drug Delivery, Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27514, USA

10. Center for Nanotechnology in Drug Delivery, Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27514, USA.

Abstract

Biotargeted nanomedicines have captured the attention of academic and industrial scientists who have been motivated by the theoretical possibilities of the ‘magic bullet’ that was first conceptualized by Paul Ehrlich at the beginning of the 20th century. The Biotargeting Working Group, consisting of more than 50 pharmaceutical scientists, engineers, biologists and clinicians, has been formed as part of the National Cancer Institute’s Alliance for Nanotechnology in Cancer to harness collective wisdom in order to tackle conceptual and practical challenges in developing biotargeted nanomedicines for cancer. In modern science and medicine, it is impossible for any individual to be an expert in every aspect of biology, chemistry, materials science, pharmaceutics, toxicology, chemical engineering, imaging, physiology, oncology and regulatory affairs. Drawing on the expertise of leaders from each of these disciplines, this commentary highlights six tenets of biotargeted cancer nanomedicines in order to enable the translation of basic science into clinical practice.

Publisher

Future Medicine Ltd

Subject

Development,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3